EDX has partnered with the intensive care unit (ICU) at Cambridge University Hospitals National Health Service (NHS) Foundation Trust (CUH) to support further development of the test.

Developed on CUH’s John Farman ICU, the test is the result of a public-private partnership involving the University of Cambridge, the UK Health Security Agency (UKHSA) and Cambridge Enterprise.

According to EDX, the test is designed to identify the DNA or RNA of the microbes that cause lung infection in critically ill patients, yielding results within 60 seconds. This enables doctors to quickly choose the most effective treatment for the patient.